This learning series has been created by Eisai to help healthcare professionals learn about Perampanel, a first-in-class highly selective, non-competitive AMPA receptor antagonist.

As a human health care (hhc) company, Eisai has adopted the corporate philosophy of giving first consideration to patients and their families and contributing to increasing their benefits. Our mission is the pursuit of this philosophy by providing services and products to meet their various health care needs worldwide while increasing our corporate value for the benefit of all our shareholders.

Perampanel is a first-in-class highly-selective, non-competitive AMPA receptor antagonist discovered and developed by Eisai. Perampanel is indicated for adjunctive treatment for partial-onset seizures with or without secondary generalized seizures in patients with epilepsy aged 12 and older. It is currently approved in more than 40 countries worldwide. Perampanel with a novel mechanism of action offers an additional therapeutic potential option for epilepsy patients with partial-onset seizures to gain seizure control and meet their treatment goals.

Eisai defines epilepsy as a therapeutic area of focus. In addition to developing Perampanel, it currently markets Zonisamide, Eslicarbazepine & Rufinamide.

Eisai hopes this e-learning series will benefit you and ultimately your patients.